Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01736475 |
Recruitment Status
:
Completed
First Posted
: November 29, 2012
Results First Posted
: September 7, 2016
Last Update Posted
: November 24, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hemophilia A | Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method Biological: PEGylated Recombinant Factor VIII | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 159 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A |
Study Start Date : | January 2013 |
Actual Primary Completion Date : | July 2014 |
Actual Study Completion Date : | July 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Prophylaxis |
Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
Pharmacokinetic (PK) evaluation of ADVATE
Other Name: ADVATE
Biological: PEGylated Recombinant Factor VIII
Pharmacokinetic (PK) evaluation of BAX 855
Other Name: BAX 855
Biological: PEGylated Recombinant Factor VIII
Prophylaxis treatment
Other Name: BAX 855
|
Experimental: On-demand |
Biological: PEGylated Recombinant Factor VIII
On-demand treatment
Other Name: BAX 855
|
- Annualized Bleeding Rate (ABR) [ Time Frame: 9 months ]Comparisons between prophylactic and on-demand treatment were based on ABR estimates from a negative binomial regression model, taking into account the treatment regimen, target joints and age at screening, and duration of the observation period for efficacy.
- Rate of Success of BAX 855 for Treatment of Bleeding Episodes [ Time Frame: At least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm and 6 months (± 2 weeks) for the on-demand arm. ]Success in the control of bleeding was defined as a rating of excellent or good using the Efficacy Rating Scale for Treatment of Bleeding Episodes measured 24 hours after initiation of treatment for the bleeding episode. EXCELLENT: Full relief of pain and cessation of objective signs of bleeding (eg, swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) after a single infusion. No additional infusion is required for the control of bleeding. Administration of further infusions to maintain hemostasis would not affect this scoring. GOOD: Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution. FAIR: Probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion. Required more than 1 infusion for complete resolution. NONE: No improvement or condition worsens.
- Average Number of BAX 855 Infusions Needed for the Treatment of Bleeding Episodes [ Time Frame: From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm]. ]
- Number of Participants With ≤1, 2, 3, 4, 5, 6, or >6 Month Time Intervals Between Bleeding Episodes or no Bleeding Episodes [ Time Frame: From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm]. ]Interval between Bleeds in months was calculated as: Observation period for efficacy (in days)/(number of bleeds)*(12/365.2425)
- Weight-adjusted Consumption of BAX 855 - Per Prophylactic Infusion and Pharmacokinetic (PK) Infusion [ Time Frame: Prophylactic Infusion: ≥50 exposure days or 6 months (±2 weeks), whichever occurs last. PK Infusion: PK #1 Pre-infusion within 30 minutes; Post-infusion 10 min, and 0.5, 1, 3, 6, 24, 32, 48, 56 hours (h). PK #2 also at Post-infusion 96h ]
- Weight-adjusted Consumption of BAX 855 - Per Treatment of Bleeding Episode (BE) and Per BE for Maintenance of Hemostasis [ Time Frame: Treatment of Bleeding Episode (BE): Minor/Moderate BE every 12 to 24 hours until bleeding is resolved; Major BE every 8 to 12 hours until bleeding is resolved. Per BE for Maintenance of Hemostasis: within 48 hours after bleeding episode resolution. ]Infusions per bleeding episode for maintenance of hemostasis only includes infusions following the resolution of a bleed to maintain hemostasis.
- Percentage of Participants With Adverse Events [ Time Frame: From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm]. ]Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Immunogenicity - Number of Participants With Positive Inhibitory Antibodies to FVIII, Binding Antibodies to FVIII, PEG-VIII, PEG and Anti-CHO Antibodies at Study Completion/Termination [ Time Frame: From first exposure to BAX 855 until the end of the study, [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm; and 6 months (± 2 weeks) for the on-demand arm]. ]
Number of participants who received BAX855, with immunogenicity data from study completion/termination visit.
FVIII = factor VIII; PEG-VIII = polyethylene glycol-factor VIII; Anti-CHO = Anti-Chinese hamster ovary
- Patient Reported Outcomes: Haemo-SYM Questionnaire, Change in Score From Baseline to End of Study [ Time Frame: Baseline; and end of study visit [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm and 6 months (± 2 weeks) for the on-demand arm]. ]
The HAEMO-SYM has two subscales: pain and bleeds. HAEMO-SYM subscale scores are calculated by taking the mean of the items in each subscale and transforming them to a 0 (none or absent) to 100 (very severe) scale.
Given that higher scores indicate more severe symptoms on the Haemo-SYM and that the change scores were calculated as the value at study completion minus the value at baseline, a negative change score indicates an improvement (reduction in symptoms). Conversely, a positive change score indicates worsening symptoms.
- Patient Reported Outcomes - Short Form (SF)-36, Change From Baseline to End of Study [ Time Frame: Baseline; and end of study visit [at least 50 exposure days or 6 months (±2 weeks), whichever occurs last, for the prophylaxis arm and 6 months (± 2 weeks) for the on-demand arm] ]Change from Baseline to End of Study for SF-36 Questionnaire is provided. Scores for individual SF-36 categories range from 0 to 100 with higher scores representing better health. Given that higher scores indicate better health-related quality of life (HRQoL) and that the change scores were calculated as the value at study completion minus the value at baseline, a negative change score indicates a worsening of HRQoL.
- Pharmacokinetics (Pk) - Plasma Half-life (One-stage Clotting Assay) [ Time Frame: Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only). ]
Terminal half-life calculated as log_e2/λz where λz is the terminal elimination rate constant.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).
- Pharmacokinetics (Pk) - Mean Residence Time (One-stage Clotting Assay) [ Time Frame: Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only). ]
The mean residence time (MRT) w as calculated as total area under the moment curve divided by the total area under the curve starting from the begin of infusion (or the end of infusion if start time is not available).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).
- Pharmacokinetics (Pk) - Total Body Clearance (One-stage Clotting Assay) [ Time Frame: Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only). ]
Clearance in dL/(kg.h) will be calculated as the dose in IU/kg divided by the total area under the curve starting from the begin of infusion (or the end of infusion if start time is not available).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).
- Pharmacokinetics (Pk) - Incremental Recovery Over Time (One-stage Clotting Assay) [ Time Frame: Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only). ]
Incremental recovery (IR) in (IU/dL)/ (IU/kg) calculated as: IR = (Cmax- (C pre-infusion)) / (Dose/kg), where C =concentration.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).
- Pharmacokinetics (Pk) - Area Under the Concentration Versus Time Curve From 0 to Infinity (AUC0-∞) (One-stage Clotting Assay) [ Time Frame: Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only). ]
Calculated by WinNonlin NCA (Model 201, calculation method: Linear Trapezoidal Linear/Log Interpolation).
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).
- Pharmacokinetics (Pk) - Apparent Volume of Distribution at Steady State (Vss) (One-stage Clotting Assay) [ Time Frame: Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only). ]
The apparent volume of distribution at steady state (Vss) will be calculated as: Vss = Clearance * Mean Residence Time.
Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).
- Pharmacokinetics (Pk) - Maximum Plasma Concentration (Cmax) (One-stage Clotting Assay) [ Time Frame: Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only). ]Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).
- Pharmacokinetics (Pk) -Time to Maximum Concentration in Plasma (Tmax) (One-stage Clotting Assay) [ Time Frame: Within 30 minutes prior to start of infusion; and post-infusion at 10, 30 minutes, and 1, 3, 6, 9, 24, 32, 48, 56, 72 (PK2 and PK3 only), and 96 hours (PK2 and PK3 only). ]Tmax in hours will be defined as the time to reach Cmax. Participants in the pharmacokinetic full analysis set (PKFAS) analysis set received an initial infusion of ADVATE for pharmacokinetic analysis (PK-1) followed by a washout period and an infusion of BAX 855 for a second pharmacokinetic analysis (PK-2). After at least 50 EDs of BAX 855, participants in the PK subgroup received another infusion of BAX 855 for pharmacokinetic analysis (PK-3).
- Change in Vital Signs From Screening - Temperature [ Time Frame: Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination ]
- Change in Vital Signs From Screening - Pulse Rate [ Time Frame: Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination ]
- Change in Vital Signs From Screening - Respiratory Rate [ Time Frame: Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination ]
- Changes in Vital Signs From Screening - Blood Pressure [ Time Frame: Screening, week 2, week 4, exposure day 10-15, month 3, study completion/termination ]Systolic Blood Pressure (SBP) Diastolic Blood Pressure (DBP)
- Changes in Clinical Chemistry Laboratory Assessments From Screening - Albumin and Protein [ Time Frame: Screening, week 2, week 4, month 3, study completion/termination ]
- Changes in Clinical Chemistry Laboratory Assessments From Screening - Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase [ Time Frame: Screening, week 2, week 4, month 3, study completion/termination ]Alkaline Phosphatase (Alk Phos); Alanine Aminotransferase (Ala Amino); Aspartate Aminotransferase (Asp Amino)
- Changes in Clinical Chemistry Laboratory Assessments From Screening - Bicarbonate, Chloride, Glucose, Potassium, Sodium, Blood Urea Nitrogen (BUN) [ Time Frame: Screening, week 2, week 4, month 3, study completion/termination ]
- Changes in Clinical Chemistry Laboratory Assessments From Screening - Creatinine, and Bilirubin [ Time Frame: Screening, week 2, week 4, month 3, study completion/termination ]
- Changes in Hematology Laboratory Assessments From Screening - Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, and Leukocytes [ Time Frame: Screening, week 2, week 4, month 3, study completion/termination ]
- Changes in Hematology Laboratory Assessments From Screening - Hematocrit [ Time Frame: Screening, week 2, week 4, month 3, study completion/termination ]
- Changes in Hematology Laboratory Assessments From Screening - Hemoglobin [ Time Frame: Screening, week 2, week 4, month 3, study completion/termination ]
- Changes in Hematology Laboratory Assessments From Screening - Erythrocytes [ Time Frame: Screening, week 2, week 4, month 3, study completion/termination ]
- Changes in Lipid Panel Assessments From Screening - Cholesterol; High Density Lipoprotein (HDL); Low Density Lipoprotein (LDL); Triglycerides; and Very Low Density Lipoprotein (VLDL) [ Time Frame: Screening, week 2, week 4, month 3, study completion/termination ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years to 65 Years (Child, Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
- Participant and/or legal representative has/have voluntarily provided signed informed consent
- Participant is 12 to 65 years old at the time of screening
- Participant is male with severe hemophilia A (Factor VIII (FVIII) clotting activity < 1%) as confirmed by central laboratory at screening after the appropriate washout period or a documented FVIII clotting activity <1%
- Participant has been previously treated with plasma-derived FVIII concentrates or recombinant FVIII for ≥150 documented exposure days (EDs)
- Participant is currently receiving prophylaxis or on-demand therapy with FVIII
- Participant is willing and able to comply with the requirements of the protocol
Main Exclusion Criteria:
- Participant has detectable FVIII inhibitory antibodies (≥ 0.6 Bethesda Units (BU) using the Nijmegen modification of the Bethesda assay) as confirmed by central laboratory at screening
- Participant has history of FVIII inhibitory antibodies (≥ 0.4 BU using the Nijmegen modification of the Bethesda assay or ≥ 0.6 BU using the Bethesda assay) at any time prior to screening
- Participant has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia A (eg, qualitative platelet defect or von Willebrand's disease).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01736475

United States, Colorado | |
University of Colorado | |
Aurora, Colorado, United States, 80045 | |
United States, Florida | |
University of Florida, College of Medicine | |
Gainesville, Florida, United States, 32610 | |
United States, Georgia | |
Children's Healthcare of Atlanta | |
Atlanta, Georgia, United States, 30322 | |
United States, Illinois | |
Bleeding and Clotting Disorders Institute | |
Peoria, Illinois, United States, 61614 | |
United States, Kentucky | |
University of Kentucky Medical Center | |
Lexington, Kentucky, United States, 40504 | |
University of Louisville Hospital | |
Louisville, Kentucky, United States, 40202 | |
United States, Louisiana | |
Tulane University Medical School | |
New Orleans, Louisiana, United States, 70124 | |
United States, Missouri | |
Children's Mercy Hospitals & Clinics | |
Kansas City, Missouri, United States, 66211 | |
United States, New York | |
Weill Cornell Medical College-New York Presbyterian Hospital | |
New York, New York, United States, 10065 | |
United States, North Carolina | |
University of North Carolina Chapel Hill | |
Chapel Hill, North Carolina, United States, 27599 | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Ohio | |
Cincinnati Children's Hospital Medical Center | |
Cincinnati, Ohio, United States, 45229 | |
The Cleveland Clinic Foundation | |
Cleveland, Ohio, United States, 44195 | |
United States, Pennsylvania | |
Penn State Milton S. Hershey Medical Center | |
Hershey, Pennsylvania, United States, 17033 | |
United States, South Carolina | |
Palmetto Health | |
Columbia, South Carolina, United States, 29203 | |
United States, Utah | |
University of Utah Health Sciences Center | |
Salt Lake City, Utah, United States, 84132 | |
United States, Washington | |
Puget Sound Blood Group | |
Seattle, Washington, United States, 98104 | |
Australia, South Australia | |
Royal Adelaide Hospital | |
Adelaide, South Australia, Australia, 5000 | |
Australia, Victoria | |
The Alfred Hospital | |
Clayton, Victoria, Australia, 3168 | |
Australia, Western Australia | |
Fremantle Hospital | |
Fremantle, Western Australia, Australia, 6160 | |
Hollywood Specialist Centre | |
Nedlands, Western Australia, Australia, 6009 | |
Austria | |
Landes-Frauen-und Kinderklinik Linz | |
Linz, Austria, 4020 | |
AKH - Medizinische Universität Wien | |
Vienna, Austria, 1090 | |
Bulgaria | |
SHAT of Oncohaematology Diseases | |
Sofia, Bulgaria, 1527 | |
Czechia | |
Fakultni nemocnice Brno | |
Brno, Czechia, 61300 | |
Fakultni nemocnice Olomouc | |
Olomouc, Czechia, 775 20 | |
Fakultni nemocnice v Motole | |
Praha 5, Czechia, 150 06 | |
Germany | |
Gerinnungszentrum Rhein-Ruhr | |
Duisburg, Nordrhein Westfalen, Germany, 47051 | |
Vivantes Klinikum im Friedrichshain - Landsberger Allee | |
Berlin, Germany, 10249 | |
Universitaetsklinikum Hamburg-Eppendorf | |
Hamburg, Germany, 20246 | |
Werlhof-Institut MVZ | |
Hannover, Germany, 30159 | |
Israel | |
Rambam Health Care Campus | |
Haifa, Israel, 3109601 | |
Chaim Sheba Medical Center | |
Tel Aviv, Israel, 64239 | |
Japan | |
Nagoya University Hospital | |
Nagoya-shi, Aichi-Ken, Japan, 466-8560 | |
University of Occupational and Environmental Health Hospital | |
Kitakyushu-shi, Fukuoka-Ken, Japan, 807-8556 | |
Hiroshima University Hospital | |
Hiroshima-shi, Hiroshima-Ken, Japan, 734-8551 | |
Hyogo College of Medicine Hospital | |
Nishinomiya-shi, Hyogo-Ken, Japan, 663-8501 | |
St. Marianna University School of Medicine Hospital | |
Kawasaki-shi, Kanagawa-Ken, Japan, 216-8511 | |
Nara Medical University Hospital | |
Kashihara-shi, Nara-Ken, Japan, 634-8522 | |
Tokyo Medical University Hospital | |
Shinjuku-ku, Tokyo-To, Japan, 160-0023 | |
Ogikubo Hospital | |
Suginami-ku, Tokyo-To, Japan, 167-8515 | |
Korea, Republic of | |
Chonnam National University Hwasun Hospital | |
Hwasun-gun, Jeollanam-do, Korea, Republic of, 519-763 | |
Pusan National University Hospital | |
Busan, Korea, Republic of, 602-739 | |
Eulji University Hospital | |
Daejeon, Korea, Republic of, 302-120 | |
Kyung hee University Hospital at Gangdong | |
Seoul, Korea, Republic of, 134-727 | |
Ulsan University Hospital | |
Ulsan, Korea, Republic of, 682-714 | |
Lithuania | |
Vilnius University Hospital Santariskiu Clinics, Public Institution | |
Vilnius, Lithuania, 08661 | |
Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos | |
Vilnius, Lithuania, LT-08406 | |
Malaysia | |
Penang General Hospital | |
Penang, Pulau Pinang, Malaysia, 10990 | |
Hospital Tengku Ampuan Rahimah | |
Klang, Selangor, Malaysia, 41200 | |
Pusat Darah Negara | |
Kuala Lumpur, Malaysia, 50400 | |
Netherlands | |
Academisch Medisch Centrum | |
Amsterdam, Netherlands, 1105 AZ | |
Poland | |
Uniwersyteckie Centrum Kliniczne | |
Gdansk, Poland, 80-952 | |
Wojewodzki Szpital Specjalistyczny im.M.Kopernika w Lodzi | |
Lodz, Poland, 93-510 | |
Romania | |
Sanador SRL | |
Bucuresti, Romania, 011026 | |
Spain | |
Hospital Universitari Son Espases | |
Palma de Mallorca, Baleares, Spain, 07010 | |
Complejo Hospitalario Universitario A Coruña | |
A Coruña, La Coruña, Spain, 15006 | |
Hospital Regional Universitario de Malaga | |
Malaga, Málaga, Spain, 29010 | |
Hospital Universitari i Politecnic La Fe | |
Valencia, Spain, 46026 | |
Sweden | |
Skånes Universitetssjukhus, Malmö | |
Malmö, Sweden, 20502 | |
Karolinska Universitetssjukhuset, Solna | |
Stockholm, Sweden, 17176 | |
Switzerland | |
Universitatsspital Zurich | |
Zurich, Switzerland, 8091 | |
Taiwan | |
Tri-Service General Hospital | |
Taipei, Taiwan, 11490 | |
Ukraine | |
SI V.K.Gusak Emergency and Reconstructive Surgery Institute of NAMSU Center of IT | |
Donetsk, Ukraine, 83045 | |
SI Institute of Blood Pathology and Transfusion Medicine of NAMSU | |
Lviv, Ukraine, 79044 | |
United Kingdom | |
Bristol Royal Hospital for Children | |
Bristol, Avon, United Kingdom, BS2 8BJ | |
Royal Free Hospital | |
London, Greater London, United Kingdom, NW3 2QG | |
St Thomas' Hospital | |
London, Greater London, United Kingdom, SE1 7EH | |
Manchester Royal Infirmary | |
Manchester, Greater Manchester, United Kingdom, M13 9WL | |
Royal Manchester Children's Hospital | |
Manchester, Greater Manchester, United Kingdom, M13 9WL | |
Leicester Royal Infirmary | |
Leicester, Leicestershire, United Kingdom, LE1 5WW | |
Churchill Hospital | |
Oxford, Oxfordshire, United Kingdom, OX3 7LJ |
Study Director: | Brigitt Abbuehl, MD | Baxter Innovations GmbH |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Baxalta now part of Shire |
ClinicalTrials.gov Identifier: | NCT01736475 History of Changes |
Other Study ID Numbers: |
261201 2012-003599-38 ( EudraCT Number ) |
First Posted: | November 29, 2012 Key Record Dates |
Results First Posted: | September 7, 2016 |
Last Update Posted: | November 24, 2017 |
Last Verified: | July 2016 |
Additional relevant MeSH terms:
Hemophilia A Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Coagulation Protein Disorders |
Hemorrhagic Disorders Genetic Diseases, Inborn Factor VIII Coagulants |